These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2006804)

  • 1. Successful drug-specific chronotherapy with the H2 blocker famotidine in the symptomatic relief of gastroesophageal reflux disease.
    Humphries TJ; Root JK; Hufnagel K
    Ann N Y Acad Sci; 1991; 618():517. PubMed ID: 2006804
    [No Abstract]   [Full Text] [Related]  

  • 2. Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group.
    Sabesin SM; Berlin RG; Humphries TJ; Bradstreet DC; Walton-Bowen KL; Zaidi S
    Arch Intern Med; 1991 Dec; 151(12):2394-400. PubMed ID: 1746996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical therapy for gastroesophageal reflux disease. Not all treatments are equal!
    Fennerty MB; Sampliner RE
    Arch Intern Med; 1991 Dec; 151(12):2365-6. PubMed ID: 1746991
    [No Abstract]   [Full Text] [Related]  

  • 4. Tolerance to H2 receptor antagonist correlates well with the decline in efficacy against gastroesophageal reflux in patients with gastroesophageal reflux disease.
    Furuta K; Adachi K; Komazawa Y; Mihara T; Miki M; Azumi T; Fujisawa T; Katsube T; Kinoshita Y
    J Gastroenterol Hepatol; 2006 Oct; 21(10):1581-5. PubMed ID: 16928220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of H2-blockers and proton pump inhibitors on intragastric acidity and intraesophageal pH in patients with gastroesophageal reflux disease].
    Ivanov AN; Iakovenko EP; Iakovenko AV
    Eksp Klin Gastroenterol; 2004; (4):16-20, 107. PubMed ID: 15568661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
    Adachi K; Hashimoto T; Komazawa Y; Mihara T; Furuta K; Fujishiro H; Ishihara S; Amano Y; Hattori S; Kinoshita Y
    Dig Liver Dis; 2005 Jul; 37(7):485-90. PubMed ID: 15975534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastroesophageal reflux and histamine2 antagonists.
    Bell SG
    Neonatal Netw; 2003; 22(2):53-7. PubMed ID: 12696725
    [No Abstract]   [Full Text] [Related]  

  • 8. Famotidine in gastroesophageal reflux disease (GERD).
    Wesdorp IC
    Hepatogastroenterology; 1992 Feb; 39 Suppl 1():24-6. PubMed ID: 1577391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Famotidine in the management of gastro-oesophageal reflux.
    Okoth FA; Lule GN; Ogutu EO; Pilczer S; Dubois C
    East Afr Med J; 1994 Jan; 71(1):44-8. PubMed ID: 8055765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease.
    Wada T; Sasaki M; Kataoka H; Tanida S; Itoh K; Ogasawara N; Oshima T; Togawa S; Kubota E; Yamada T; Mori Y; Fujita F; Ohara H; Nakao H; Sobue S; Joh T; Itoh M
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():2-9. PubMed ID: 15943840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisecretory drugs, Helicobacter pylori infection and symptom relief in GORD: still an unexplored triangle.
    Scarpignato C
    Dig Liver Dis; 2005 Jul; 37(7):468-74. PubMed ID: 15893968
    [No Abstract]   [Full Text] [Related]  

  • 12. The efficacy of hydrotalcite compared with OTC famotidine in the on-demand treatment of gastroesophageal reflux disease: a non-inferiority trial.
    Konturek JW; Beneke M; Koppermann R; Petersen-Braun M; Weingärtner U
    Med Sci Monit; 2007 Jan; 13(1):CR44-9. PubMed ID: 17179910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
    Malcolm WF; Gantz M; Martin RJ; Goldstein RF; Goldberg RN; Cotten CM;
    Pediatrics; 2008 Jan; 121(1):22-7. PubMed ID: 18166553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Symptomatic therapy with famotidine in non-erosive gastro-esophageal reflux. Results of an open multicenter study].
    Heckers H; Lübbecke F
    Arzneimittelforschung; 1995 Apr; 45(4):499-504. PubMed ID: 7779150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of gastrosidine (famotidine) in the treatment of gastroesophageal reflux at the reflux esophagitis stage].
    Vasil'ev IuV; Li IA
    Eksp Klin Gastroenterol; 2002; (4):30-3, 131. PubMed ID: 12503271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of H2 receptor antagonists in the treatment of gastroesophageal reflux disease and its symptoms.
    Tougas G; Armstrong D
    Can J Gastroenterol; 1997 Sep; 11 Suppl B():51B-54B. PubMed ID: 9347179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of mild to moderate reflux esophagitis with the H2-blocker famotidine].
    Kratochvil P; Brandstätter G; Janisch P
    Wien Med Wochenschr; 1992; 142(18):418-22. PubMed ID: 1475988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study of the speed of acid-suppressing effects of oral administration of cimetidine and famotidine.
    Adachi K; Komazawa Y; Mihara T; Azumi T; Fujisawa T; Katsube T; Furuta K; Kinoshita Y
    J Gastroenterol Hepatol; 2005 Jul; 20(7):1012-5. PubMed ID: 15955208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.
    Fujiwara Y; Higuchi K; Nebiki H; Chono S; Uno H; Kitada K; Satoh H; Nakagawa K; Kobayashi K; Tominaga K; Watanabe T; Oshitani N; Arakawa T
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():10-8. PubMed ID: 15943841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review: the efficacy of intermittent and on-demand therapy with histamine H2-receptor antagonists or proton pump inhibitors for gastro-oesophageal reflux disease patients.
    Zacny J; Zamakhshary M; Sketris I; Veldhuyzen van Zanten S
    Aliment Pharmacol Ther; 2005 Jun; 21(11):1299-312. PubMed ID: 15932360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.